secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001534120-26-000028
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics Phase 2 LOTUS trial meets primary endpoint; HiSCR75 rates 42.2% and 42.9% for abdakibart in HS
--------------------------------------------------------------------------------

- Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.
- Statistically significant benefit on secondary endpoints HiSCR50, change in IHS4, and draining tunnel count.
- Abdakibart well tolerated; most TEAEs mild to moderate, no neutropenia, serious infections, or opportunistic infections.
- Response similar in patients with and without prior biologic exposure.
- Avalo plans to advance abdakibart into a registrational Phase 3 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/0001534120-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/avtx-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer